145 related articles for article (PubMed ID: 7923602)
1. Gene expression in X-irradiated human tumour cell lines expressing cisplatin resistance and altered DNA repair capacity.
Taverna P; Hansson J; Scanlon KJ; Hill BT
Carcinogenesis; 1994 Sep; 15(9):2053-6. PubMed ID: 7923602
[TBL] [Abstract][Full Text] [Related]
2. Enhanced DNA repair and tolerance of DNA damage associated with resistance to cis-diammine-dichloroplatinum (II) after in vitro exposure of a human teratoma cell line to fractionated X-irradiation.
Hill BT; Shellard SA; Hosking LK; Fichtinger-Schepman AM; Bedford P
Int J Radiat Oncol Biol Phys; 1990 Jul; 19(1):75-83. PubMed ID: 2380098
[TBL] [Abstract][Full Text] [Related]
3. Characterisation of the unusual expression of cross resistance to cisplatin in a series of etoposide-selected resistant sublines of the SuSa testicular teratoma cell line.
Shellard SA; Hosking LK; Hill BT
Biochem Pharmacol; 1994 Mar; 47(5):775-9. PubMed ID: 8135853
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms associated with the expression of cisplatin resistance in a human ovarian tumor cell line following exposure to fractionated X-irradiation in vitro.
Dempke WC; Shellard SA; Hosking LK; Fichtinger-Schepman AM; Hill BT
Carcinogenesis; 1992 Jul; 13(7):1209-15. PubMed ID: 1638688
[TBL] [Abstract][Full Text] [Related]
5. Use of host cell reactivation of cisplatin-treated adenovirus 5 in human cell lines to detect repair of drug-treated DNA.
Maynard KR; Hosking LK; Hill BT
Chem Biol Interact; 1989; 71(4):353-65. PubMed ID: 2582540
[TBL] [Abstract][Full Text] [Related]
6. Differential formation and enhanced removal of specific cisplatin-DNA adducts in two cisplatin-selected resistant human testicular teratoma sublines.
Hill BT; Shellard SA; Fichtinger-Schepman AM; Schmoll HJ; Harstrick A
Anticancer Drugs; 1994 Jun; 5(3):321-8. PubMed ID: 7919457
[TBL] [Abstract][Full Text] [Related]
7. Deficient repair of cisplatin-DNA adducts identified in human testicular teratoma cell lines established from tumours from untreated patients.
Hill BT; Scanlon KJ; Hansson J; Harstrick A; Pera M; Fichtinger-Schepman AM; Shellard SA
Eur J Cancer; 1994; 30A(6):832-7. PubMed ID: 7917544
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin sensitivity/resistance in UV repair-deficient Chinese hamster ovary cells of complementation groups 1 and 3.
Lee KB; Parker RJ; Bohr V; Cornelison T; Reed E
Carcinogenesis; 1993 Oct; 14(10):2177-80. PubMed ID: 8222071
[TBL] [Abstract][Full Text] [Related]
9. Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene.
Yu JJ; Lee KB; Mu C; Li Q; Abernathy TV; Bostick-Bruton F; Reed E
Int J Oncol; 2000 Mar; 16(3):555-60. PubMed ID: 10675489
[TBL] [Abstract][Full Text] [Related]
10. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines.
Selvakumaran M; Pisarcik DA; Bao R; Yeung AT; Hamilton TC
Cancer Res; 2003 Mar; 63(6):1311-6. PubMed ID: 12649192
[TBL] [Abstract][Full Text] [Related]
11. Expression of collateral sensitivity to cisplatin, methotrexate, and fluorouracil in a human ovarian carcinoma cell line following exposure to fractionated x-irradiation in vitro.
Dempke WC; Hosking LK; Hill BT
Semin Oncol; 1992 Apr; 19(2 Suppl 3):66-72. PubMed ID: 1557659
[TBL] [Abstract][Full Text] [Related]
12. Multiple mechanisms of resistance in a series of human testicular teratoma cell lines selected for increasing resistance to etoposide.
Hosking LK; Whelan RD; Shellard SA; Davies SL; Hickson ID; Danks MK; Hill BT
Int J Cancer; 1994 Apr; 57(2):259-67. PubMed ID: 7908897
[TBL] [Abstract][Full Text] [Related]
13. Elevated expression of thymidylate synthase cycle genes in cisplatin-resistant human ovarian carcinoma A2780 cells.
Scanlon KJ; Kashani-Sabet M
Proc Natl Acad Sci U S A; 1988 Feb; 85(3):650-3. PubMed ID: 3422447
[TBL] [Abstract][Full Text] [Related]
14. Messenger RNA expression of resistance proteins and related factors in human ovarian carcinoma cell lines resistant to doxorubicin, taxol and cisplatin.
Masanek U; Stammler G; Volm M
Anticancer Drugs; 1997 Feb; 8(2):189-98. PubMed ID: 9073315
[TBL] [Abstract][Full Text] [Related]
15. Cisplatin-DNA damage recognition proteins in human tumour extracts.
Bissett D; McLaughlin K; Kelland LR; Brown R
Br J Cancer; 1993 Apr; 67(4):742-8. PubMed ID: 8471431
[TBL] [Abstract][Full Text] [Related]
16. Identification of a distinctive P-glycoprotein-mediated resistance phenotype in human ovarian carcinoma cells after their in vitro exposure to fractionated X-irradiation.
Hill BT; Whelan RD; Hurst HC; McClean S
Cancer; 1994 Jun; 73(12):2990-9. PubMed ID: 7911070
[TBL] [Abstract][Full Text] [Related]
17. Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines.
Mamenta EL; Poma EE; Kaufmann WK; Delmastro DA; Grady HL; Chaney SG
Cancer Res; 1994 Jul; 54(13):3500-5. PubMed ID: 8012973
[TBL] [Abstract][Full Text] [Related]
18. Effects of gemcitabine on cis-platinum-DNA adduct formation and repair in a panel of gemcitabine and cisplatin-sensitive or -resistant human ovarian cancer cell lines.
Peters GJ; Van Moorsel CJ; Lakerveld B; Smid K; Noordhuis P; Comijn EC; Weaver D; Willey JC; Voorn D; Van der Vijgh WJ; Pinedo HM
Int J Oncol; 2006 Jan; 28(1):237-44. PubMed ID: 16328001
[TBL] [Abstract][Full Text] [Related]
19. Lentivirus-Mediated RNAi silencing targeting ERCC1 reverses cisplatin resistance in cisplatin-resistant ovarian carcinoma cell line.
Du P; Zhang X; Liu H; Chen L
DNA Cell Biol; 2015 Jul; 34(7):497-502. PubMed ID: 25941922
[TBL] [Abstract][Full Text] [Related]
20. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
Schmidt W; Chaney SG
Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
